Opportunities and challenges of personalized therapy of patients with HR ALL

The opportunities: Novel genomic diagnostics and availability of multiple new drugs create opportunities for personalized adjustment of therapy for HR ALL patients. The major challenges: Lack of reliable efficacy data and of specific clinical trials. Recommendations: Be conservative minimize deviations from clinical protocols; Whenever possible enroll the patient in a specific clinical trial for the novel therapy; If not available–maximize local and central prospective collection of clinical and biological data on each patient.

• Publication year

  2019

• Venue

  HemaSphere

• Publication date

  2019-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/HS9.0000000000000229PMID 35309807PMCID 8925720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL.

  2019cited by this paper
• PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

  2019cited by this paper
• Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

  2018cited by this paper
• Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.

  2018cited by this paper
• PAX 5-driven subtypes of B-progenitor acute lymphoblastic leukemia

  2018cited by this paper
• Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

  2018cited by this paper
• PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.

  2018cited by this paper
• ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.

  2018cited by this paper
• Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

  2018cited by this paper
• Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report

  2017cited by this paper
• Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome

  2017cited by this paper
• Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

  2017cited by this paper
• Research methods to change clinical practice for patients with rare cancers.

  2016cited by this paper
• EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.

  2016cited by this paper
• Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia

  2016cited by this paper
• TKI dasatinib monotherapy for a patient with Ph‐like ALL bearing ATF7IP/PDGFRB translocation

  2015cited by this paper
• Beyond Philadelphia: ‘Ph-like’ B cell precursor acute lymphoblastic leukemias – diagnostic challenges and therapeutic promises

  2014cited by this paper
• Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

  2014cited by this paper
• Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

  2014cited by this paper
• Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

  2013cited by this paper
• Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia

  2013cited by this paper
• Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

  2013cited by this paper
• Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

  2012cited by this paper

• No citing papers are available for this paper.